Brokerages expect Immatics (NASDAQ:IMTX) to post ($0.31) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Immatics’ earnings, with estimates ranging from ($0.34) to ($0.28). Immatics posted earnings per share of ($0.46) during the same quarter last year, which indicates a positive year over year growth rate of 32.6%. The company is expected to report its next quarterly earnings results on Wednesday, December 1st.
On average, analysts expect that Immatics will report full year earnings of ($1.55) per share for the current year, with EPS estimates ranging from ($1.75) to ($1.38). For the next fiscal year, analysts anticipate that the company will report earnings of ($1.77) per share, with EPS estimates ranging from ($2.00) to ($1.50). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Immatics.
Immatics (NASDAQ:IMTX) last released its earnings results on Tuesday, August 10th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The firm had revenue of $6.25 million during the quarter, compared to analyst estimates of $10.15 million.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Edmond DE Rothschild Holding S.A. acquired a new position in Immatics during the 1st quarter worth approximately $25,000. Citigroup Inc. increased its position in Immatics by 139.9% during the 1st quarter. Citigroup Inc. now owns 3,409 shares of the company’s stock worth $38,000 after purchasing an additional 1,988 shares during the period. Jump Financial LLC acquired a new position in Immatics during the 2nd quarter worth approximately $146,000. State Street Corp acquired a new position in Immatics during the 2nd quarter worth approximately $328,000. Finally, HighTower Advisors LLC acquired a new position in Immatics during the 1st quarter worth approximately $336,000. Institutional investors own 33.38% of the company’s stock.
Immatics stock traded down $0.36 during trading on Tuesday, reaching $12.92. 143,100 shares of the company were exchanged, compared to its average volume of 352,361. Immatics has a 52-week low of $9.53 and a 52-week high of $18.42. The company has a market capitalization of $812.78 million, a P/E ratio of -7.10 and a beta of -0.02. The stock’s 50 day simple moving average is $12.90 and its two-hundred day simple moving average is $12.25.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Read More: What is a good dividend yield?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.